Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing SOPHiA GENETICS’ filings can feel like decoding the human genome itself—dense pages on machine-learning algorithms, data-privacy controls, and global regulatory paths. If you’ve ever asked, “How do I read the SOPHiA GENETICS annual report 10-K simplified?” or searched for “SOPHiA GENETICS insider trading Form 4 transactions,” this page was built for you.
Stock Titan’s AI instantly converts every new document—whether a 10-Q quarterly earnings report or an 8-K material event—into plain-English highlights. Want segment metrics on cloud-based diagnostics? Our engine flags them. Tracking “SOPHiA GENETICS executive stock transactions Form 4” before a pipeline announcement? Real-time alerts mean you never miss a trade.
Here’s what you’ll uncover:
- 10-K & 10-Q: Drill into R&D spend, SaaS subscription growth, and data-security disclosures with our AI-powered summaries—perfect for anyone Googling “understanding SOPHiA GENETICS SEC documents with AI.”
- Form 4: Live feed of “SOPHiA GENETICS Form 4 insider transactions real-time,” tracking how executives manage equity tied to precision-oncology milestones.
- Proxy statements: Clarity on “SOPHiA GENETICS proxy statement executive compensation,” including stock-option grants for bioinformatics talent.
- 8-K events: Immediate context when the company files “SOPHiA GENETICS 8-K material events explained,” whether it’s a new hospital network partnership or regulatory approval update.
Every filing is refreshed straight from EDGAR the moment it posts. Our concise AI commentary surfaces what drives revenue, highlights key risk factors, and answers common questions like “SOPHiA GENETICS earnings report filing analysis” without forcing you to wade through footnotes. Complex genomics disclosures made clear—so you can focus on decisions, not documentation.
SOPHiA GENETICS SA (SOPH) filed a Form 144 disclosing a proposed sale of 83,558 common shares through Morgan Stanley Smith Barney with an aggregate market value of $345,094.54 and an approximate sale date of 09/29/2025. The filing shows acquisition details: 42,729 shares as founders' shares acquired 03/18/2011 and 40,829 shares from restricted stock units dated 10/02/2025. The filer also reported multiple recent Rule 10b5-1 sales and an individual sale totaling 40,829 shares on 08/19/2025 with gross proceeds of $142,493.21. The notice includes the required representation regarding absence of undisclosed material information.
SOPHiA GENETICS SA (SOPH) Form 144 notice discloses a proposed sale of 10,415 common shares through Morgan Stanley Smith Barney on 09/26/2025 with an aggregate market value of $35,723.45. The shares were acquired as founders' shares on 03/18/2011. The filing also lists multiple recent dispositions by the same person, including several 10b5-1 plan sales and one direct sale of 40,829 shares on 08/19/2025. Total shares reported sold in the past three months sum to 83,725 shares. The filer affirms no undisclosed material adverse information and references compliance with Rule 10b5-1 where applicable.
SOPHiA GENETICS SA reporting a Form 144 notice: an insider proposes to sell 21,000 common shares through Morgan Stanley Smith Barney on 09/23/2025 on NASDAQ with an aggregate market value of $82,530.00. The shares were acquired 06/24/2024 in a Pre-IPO transaction from the issuer and were paid for on the acquisition date. Total shares outstanding reported are 67,579,560, so the proposed sale equals approximately 0.031% of outstanding shares. The filer certifies no undisclosed material adverse information and provides no other sales in the past three months.
Form 144 filed for SOPHiA GENETICS SA (SOPH) reports a proposed sale of 40,829 common shares through Morgan Stanley Smith Barney with an aggregate market value of $142,493.21, with an approximate sale date of 08/19/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 08/18/2025 and are being sold by the person identified in the filing. The filing also lists multiple prior 10b5-1 sales by the same person between 05/20/2025 and 07/23/2025, showing routine disposals of common shares under a trading plan. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for SOPHIA GENETICS SA (SOPH) discloses a proposed sale of 6,833 common shares through Morgan Stanley Smith Barney with an aggregate market value of $23,847.17. The filing lists the approximate sale date as 08/19/2025 and shows 67,579,560 shares outstanding. The shares were acquired as restricted stock units from the issuer on 08/18/2025 with payment noted on 08/18/2025. The filing also reports recent 10b5-1 sales by PHILIPPE MENU totaling 6,639 shares across several dates in May–July 2025 with listed gross proceeds.
SOPHiA GENETICS SA prospectus supplement discloses share capital, equity incentives and corporate governance provisions relevant to debt and equity offerings. As of June 30, 2025 the company reported options and awards that could dilute equity: 495,980 shares from an Incentive Stock Option Plan (WAEP $3.18), 2,295,990 from a 2019 plan (WAEP $4.97), 11,558,048 from a 2021 Equity Incentive Plan (WAEP $5.79), 3,194,328 RSUs, 3,838,901 additional shares reserved under the 2021 plan, 400,000 warrants (exercise $4.9992) and 11,741,660 treasury shares.
The filing also describes shareholder authority and board powers, authorized conditional share capital and a capital range enabling the board to increase or decrease share capital by up to 50% within a shareholder-determined period not exceeding five years. It lists circumstances permitting issuance without pre-emptive rights, permitted offering methods, and certain exemptions and Exchange Act obligations applicable if the company ceases to qualify as a foreign private issuer.
FAQ
What is the current stock price of Sophia Genetics Sa (SOPH)?
What is the market cap of Sophia Genetics Sa (SOPH)?
